CTLA4Ig increases the survival of B6 mice bearing B16 melanoma tumors through the reduction of melanoma metastasis in B6 mice.

<p>(A) Sex- and age- matched B6 mice were injected with 2×10⁵ B16 melanoma cells via tail vein on day 0, followed by intravenous injection of either 200 μg CTLA4Ig or 200 μg isotype control IgG on days 0, 3 and 6, respectively, and the survival time of each animal was recorded. The mortality of one representative from three experiments is shown. (B) Sex- and age- matched B6 mice were injected with 2×10⁵ B16 melanoma cells via tail vein on day 0, followed by either 2 μg CTLA4Ig or 2 μg IgG control infusion via vein on days 0, 3 and day 6, respectively, and melanoma lung metastasis was assessed on day 10. The number of metastatic nodules on the lung surface, a photomicrograph and a representative H&E staining section are shown. Data are recorded as the mean ± SD (n=10), and Student’s t test is used to compare experimental and control groups. Data represents one of three independent experiments. <b><i>*</i></b><i>p</i> < 0.05, ^**<i>p</i> < 0.01.